BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanda T, Moriyama M. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World J Gastroenterol 2017; 23(31): 5645-5649 [PMID: 28883690 DOI: 10.3748/wjg.v23.i31.5645] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 El-Kassas M, Awad A. Metabolic aspects of hepatitis C virus. World J Gastroenterol 2022; 28(22): 2429-2436 [DOI: 10.3748/wjg.v28.i22.2429] [Reference Citation Analysis]
2 González-Colominas E, Batlle M, Monge-Escartín I, Duran X, Viu A, de Antonio-Cuscó M, Grau S, Bessa X, Carrión JA. Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. Eur J Gastroenterol Hepatol 2021;32:214-22. [PMID: 32195695 DOI: 10.1097/MEG.0000000000001714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chen JJ, Lee PL, Chiu HC, Tung HD, Chiu YC, Cheng PN. Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan. J Gastroenterol Hepatol 2020;35:467-72. [PMID: 31445507 DOI: 10.1111/jgh.14845] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
4 Jang TY, Huang CI, Yeh ML, Liang PC, Tsai PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Huang CF, Chuang WL, Yu ML. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. J Gastroenterol Hepatol 2020;35:473-81. [PMID: 31414504 DOI: 10.1111/jgh.14835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
5 Wang M, Ping Y, Li Z, Li J, Zhang Z, Yue D, Chen X, Wang L, Huang L, Huang J, Yang L, Zhao X, Yang S, Li H, Shi J, Li J, Zhang Y. Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signalling. J Viral Hepat 2019;26:246-57. [PMID: 30339295 DOI: 10.1111/jvh.13024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. J Viral Hepat 2019;26:55-64. [PMID: 30265418 DOI: 10.1111/jvh.13008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
7 Mansouri A, Gattolliat CH, Asselah T. Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology 2018;155:629-47. [PMID: 30012333 DOI: 10.1053/j.gastro.2018.06.083] [Cited by in Crossref: 329] [Cited by in F6Publishing: 331] [Article Influence: 65.8] [Reference Citation Analysis]